// App-Quantinova.ai

: PP2A Inhibitor LB100 Enhances the Sensitivity of NPM-ALK+ALCL to Crizotinib and Reverses the Resistance of ALCL to Crizotinib

Researchers

Presenter

  • Wenyu Shi

Principal Investigators

  • Qingfeng Xue

  • Huan Zhou

  • Xin Hua

  • Yaping Zhang

  • Jianyong Li

Medical Centers

  • Pukou CLL Center, Pukou division of Jiangsu Province Hospital, Nanjing, China

  • Department of Hematology, Affiliated Hospital of Nantong University, Nantong, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non-Hodgkin's Lymphoma

Biomarkers

  • Protein Phosphatase 2 Phosphatase Activator

  • DNA Damage Inducible Transcript 3

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Vincristine

  • Adriamycin injection

  • Prednisone

  • Crizotinib

  • LB100

Outcome

  • N/A

Study Design

  • Safety

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved